Jupiter Topco LLC Makes New $5.07 Million Investment in Baxter International Inc. $BAX

Key Points

• Jupiter Topco LLC acquired 237,683 shares of Baxter International during the second quarter, valued at approximately $5.07 million. Institutional investors collectively own 90.19% of BAX.
• Baxter reported quarterly EPS of $0.56, exceeding the $0.37 consensus estimate, while revenue reached $2.96 billion and increased 5.3% year over year. The company maintained fiscal 2026 EPS guidance of $1.95–$2.15.
• Analyst sentiment remains mostly neutral, with a consensus “Hold” rating and a $22.45 target price, despite several firms raising their targets. BAX recently traded at $26.08 and has a 52-week range of $15.73 to $30.00.

Jupiter Topco LLC acquired a new position in Baxter International Inc. (NYSE:BAX - Free Report) during the 2nd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 237,683 shares of the medical instruments supplier's stock, valued at approximately $5,066,000.

A number of other large investors have also recently made changes to their positions in BAX. Basepoint Wealth LLC purchased a new stake in Baxter International in the 4th quarter worth approximately $26,000. Jones Financial Companies Lllp purchased a new position in Baxter International during the second quarter valued at approximately $26,000. Imprint Wealth LLC purchased a new position in Baxter International during the third quarter valued at approximately $27,000. MUFG Securities EMEA plc bought a new position in shares of Baxter International in the second quarter worth approximately $46,000. Finally, Los Angeles Capital Management LLC bought a new position in shares of Baxter International in the fourth quarter worth approximately $46,000. 90.19% of the stock is owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

Several brokerages have recently commented on BAX. Citigroup upgraded shares of Baxter International from a "sell" rating to a "neutral" rating and raised their price objective for the company from $17.00 to $28.00 in a research report on Friday, July 31st. TD Cowen increased their price target on Baxter International from $20.00 to $24.00 and gave the stock a "hold" rating in a research note on Monday, July 27th. The Goldman Sachs Group raised their price target on Baxter International from $19.00 to $21.00 and gave the company a "neutral" rating in a report on Wednesday, July 15th. Wall Street Zen raised Baxter International from a "hold" rating to a "buy" rating in a research note on Saturday, August 1st. Finally, Stifel Nicolaus increased their target price on Baxter International from $19.00 to $24.00 and gave the stock a "hold" rating in a research report on Tuesday, July 28th. Two research analysts have rated the stock with a Buy rating, nine have issued a Hold rating and two have assigned a Sell rating to the company's stock. According to data from MarketBeat, the stock currently has an average rating of "Hold" and a consensus target price of $22.45.

Baxter International Price Performance

Shares of NYSE:BAX opened at $26.08 on Tuesday. The firm has a market cap of $13.48 billion, a price-to-earnings ratio of -12.60, a P/E/G ratio of 3.96 and a beta of 0.59. The firm has a fifty day moving average price of $24.37 and a 200 day moving average price of $20.57. Baxter International Inc. has a fifty-two week low of $15.73 and a fifty-two week high of $30.00. The company has a debt-to-equity ratio of 1.39, a quick ratio of 1.32 and a current ratio of 1.95.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings results on Thursday, July 30th. The medical instruments supplier reported $0.56 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.37 by $0.19. The company had revenue of $2.96 billion for the quarter, compared to the consensus estimate of $2.80 billion. Baxter International had a negative net margin of 9.27% and a positive return on equity of 16.57%. Baxter International's revenue for the quarter was up 5.3% compared to the same quarter last year. During the same period in the previous year, the firm posted $0.59 EPS. Baxter International has set its FY 2026 guidance at 1.950-2.150 EPS. As a group, sell-side analysts expect that Baxter International Inc. will post 2.04 earnings per share for the current fiscal year.

Baxter International Dividend Announcement

The company also recently announced a quarterly dividend, which will be paid on Thursday, October 1st. Investors of record on Friday, August 28th will be given a $0.01 dividend. This represents a $0.04 dividend on an annualized basis and a dividend yield of 0.2%. The ex-dividend date is Friday, August 28th. Baxter International's payout ratio is currently -1.93%.

Baxter International Company Profile

Baxter International Inc is a global healthcare company that develops, manufactures and markets a broad portfolio of medical products, pharmaceutical therapies and biotechnology-based solutions. The company's primary business activities are organized around renal care, medication delivery, acute therapies, pharmacy automation, surgical care and biotechnology. Baxter's offerings are designed to support patient care in hospitals, dialysis centers, nursing homes and other healthcare facilities worldwide.

In the renal care segment, Baxter provides hemodialysis and peritoneal dialysis systems, water treatment equipment and related disposables, including dialyzers, bloodlines and catheters.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source